The purpose of this study is to investigate the safety and how well inhaled treprostinil works in subjects with pulmonary hypertension associated with interstitial lung disease or combined pulmonary fibrosis and emphysema. Adults over the age of 18 are eligible. Study requires at least 6 separate clinic visits over approximately a 20 week period.
Subjects are being asked to volunteer for a research study because they have their first anaplastic astrocytoma (AA) tumor progression (worsening) or recurrence.
The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Eflornithine is an experimental drug that the United States Food and Drug Administration (FDA) has not approved it for use by the general public. Lomustine has been approved by the FDA in the United States for this patient population.
This study is evaluating an investigational product called CAP-1002 Allogenic Cardiosphere ?Derived Cells. Allogenic means tissue or cells that come from another person. CAP-1002 is a product consisting of cells grown from donated heart muscle tissue. The purpose of this study is to look at the safety and feasibility of delivery of allogenic human cardiosphere derived stem cells (CDC's) through the arteries of the heart in participants with heart failure. The study will also determine if CAP-1002 might reduce clinically-meaningful adverse events, meaning some of the symptoms you are experiencing relating to your heart failure may go away and you may feel better. In this study, we will be investigating whether CAP-1002 is safe and begin to look at effectiveness in repairing heart tissue in comparison to placebo (inactive substance) control.
The purpose of this study is to test study treatments that combine an investigational drug (ONT-380) with two approved drugs (capecitabine and trastuzumab) in subjects with advanced breast cancer to find out what effects, good or bad, it may have on you and your disease.
This research study includes adults (18 years of age or older) with Idiopathic Pulmonary Fibrosis (IPF). The study is being conducted to find out if KD025 is a safe and effective treatment. Participants will be put on the study drug, KD025, for about 24 weeks (followed by another 24 weeks on KD025 if tolerated well). They will be on a daily dose of 400mg (by mouth) and in previous tests have shown to reduce IPF and inflammation.
Alcohol use disorders (AUD) and intimate partner aggression (IPA) frequently co-occur. There are significant health and economic burdens associated with AUD and co-occurring IPA, and little empirical data to guide treatment efforts. The neuropeptide oxytocin may help mitigate both AUD and IPA. However, clinical data examining oxytocin's effects on human aggression is scant. The proposed study is designed to address these gaps in the literature by utilizing a human laboratory paradigm to test the effects of oxytocin on craving and aggression among couples with AUD and co-occurring IPA.
PEPPER is a randomized study comparing the three most commonly used blood thinners in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The blood thinners being compared are enteric coated aspirin plus air pump compression, low intensity warfarin, and rivaroxaban.
The purpose of this study is to assess the effects of N-Acetylcysteine (NAC), an over-the-counter antioxidant, to assist adult cigarette smokers with quitting and preventing relapse to smoking. This medication may help people quit smoking by reducing withdrawal symptoms, craving, and preventing relapse, but we do not know if NAC helps smokers early in their quit attempt or after they have already quit.
This research protocol will be using for initial screening and assessment potential study subjects for their farther participation in the other specific research protocols/components. These research components are part of larger research protocol - Alcohol Center Grant.
This study is for patients that have been diagnosed with indolent B cell non-Hodgkin lymphoma and your disease returned or did not improve at all after receiving one or more treatments containing rituximab.The investigational drug in this study is ALT-803. The purpose of this research study is to test standard rituximab with different doses of the study drug, ALT-803, to see which dose is safer in people. Participants can expect to be in this study for 36 weeks and have evaluations of your disease for up to 5 years.